NEK10

Serine/threonine-protein kinase Nek10 · Q6ZWH5 · NEK10 on Sugi Atlas →

716 patent compounds predicted against NEK10, 574 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL14061350	1.00	1/20
Lerociclib (SCHEMBL16036885)	1.00	1/20
Lerociclib (SCHEMBL22832157)	1.00	1/20
Lerociclib (SCHEMBL30175009)	1.00	1/20
SCHEMBL15249273	0.98	1/20
Lerociclib (SCHEMBL23711495)	0.98	1/20
Lerociclib (SCHEMBL29409994)	0.98	1/20
Lerociclib (SCHEMBL29409995)	0.98	1/20
SCHEMBL24413774	0.85	1/20
SCHEMBL20980212	0.85	1/20
Trilaciclib (SCHEMBL10082028)	0.83	1/20
Trilaciclib (SCHEMBL29356370)	0.83	1/20
Trilaciclib (SCHEMBL29763763)	0.83	1/20
SCHEMBL10082029	0.83	1/20
SCHEMBL22551643	0.83	1/20
SCHEMBL19036390	0.82	1/20
SCHEMBL20926967	0.82	1/20
Trilaciclib (SCHEMBL29375833)	0.82	1/20
Trilaciclib (SCHEMBL29514690)	0.82	1/20
SCHEMBL4549924	0.82	1/20

Clinical trials — most relevant to NEK10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Biological Predictive Factors of Response to ESA in Low Risk MDS Patients	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers	PHASE1/PHASE2	RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients	PHASE1/PHASE2	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer	PHASE1	UNKNOWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma	nan	COMPLETED
Genetics of Neonatal Encephalopathy and Related Disorders	nan	RECRUITING
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NEK10 binder may also engage these)

Protein	Name	Similarity
Q3UGM2	—	0.997	Q3UGM2 →
Q9R1D7	—	0.977	Q9R1D7 →
Q08BT5	—	0.975	Q08BT5 →
Q3LAC4	—	0.973	Q3LAC4 →
PRKD1	Serine/threonine-protein kinase D1	0.971	landscape →
Q9P260	—	0.970	Q9P260 →
Q6DFZ1	—	0.970	Q6DFZ1 →
Q66H91	—	0.969	Q66H91 →
Q8VI02	—	0.969	Q8VI02 →
Q14161	—	0.969	Q14161 →
F1LTE0	—	0.969	F1LTE0 →
Q92538	—	0.968	Q92538 →
Q9Y2X7	—	0.968	Q9Y2X7 →
Q8TF05	—	0.968	Q8TF05 →
Q6ZPY2	—	0.968	Q6ZPY2 →
E1C1R4	—	0.968	E1C1R4 →
Q9ESL4	—	0.968	Q9ESL4 →
Q70Z35	—	0.967	Q70Z35 →
USP47	Ubiquitin carboxyl-terminal hydrolase 47	0.967	landscape →
Q6IC98	—	0.967	Q6IC98 →
Q5U252	—	0.967	Q5U252 →
Q8BWW9	—	0.967	Q8BWW9 →
Q9Z272	—	0.966	Q9Z272 →
Q148V7	—	0.966	Q148V7 →
Q14CM0	—	0.966	Q14CM0 →
MAP3K20	Mitogen-activated protein kinase kinase kinase 20	0.966	landscape →
Q62101	—	0.966	Q62101 →
Q8K2V1	—	0.965	Q8K2V1 →
Q5T6S3	—	0.965	Q5T6S3 →
Q96RK4	—	0.965	Q96RK4 →